TELA Bio, Inc. — fact timeline

TELA Bio, Inc. shareholders approved Approval of an amendment to the TELA Bio, Inc. Amended and Restated 2019 Equity Incentive Plan to, among other things, increase the authorized shares issuable thereunder by 3,500,000 shares. at the 2026-04-24 meeting.

“Proposal 4 - Approval of an amendment to the TELA Bio, Inc. Amended and Restated 2019 Equity Incentive Plan to, among other things, increase the authorized shares issuable thereunder by 3,500,000 shares. The Plan Amendment was approved, as follows: Votes For Votes Against Abstentions Broker Non-Votes 27,256,266 538,830 16,593 5,650,509”

TELA Bio, Inc. shareholders approved Approval, on a non-binding advisory basis, of the compensation of the Company’s named executive officers. at the 2026-04-24 meeting.

“Proposal 3 - Approval, on a non-binding advisory basis, of the compensation of the Company’s named executive officers. The stockholders approved, on a non-binding advisory basis, the compensation of the Company’s named executive officers, as follows: Votes For Votes Against Abstentions Broker Non-Votes 20,891,695 6,900,032 19,962 5,650,509”

TELA Bio, Inc. shareholders approved Election of Class I Directors at the 2026-04-24 meeting.

“Proposal 1 - Election of Class I Directors . Each of Joseph Capper, Betty Jo Rocchio and William Plovanic were elected to the Board to serve as Class I directors until the 2029 Annual Meeting of Stockholders and until their successors, if any, are elected or appointed, or their earlier death, resignation, retirement, disqualification or removal, as follows: Name For Withheld Broker Non-Votes Joseph Capper 27,244,482 567,207 5,650,509 Betty Jo Rocchio 27,595,955 215,734 5,650,509 William Plovanic 27,497,453 314,236 5,650,509”

TELA Bio, Inc. reported first quarter ended March 31, 2026 results: revenue $19.1 million, net income Net loss was $12.3 million. Guidance reaffirmed.

“at the conclusion of the 2026 Annual Meeting on June 9, 2026; · Noted the U.S. commercial organization is fully staffed at planned 2026 levels; · Delivered revenue of $19.1 million in the first quarter of 2026, representing growth of 3% over the prior year period; · Accelerated European revenue growth to 41% over the prior year period, with continued”

TELA Bio, Inc. reported quarter ended March 31, 2026 results: revenue approximately $19.0 million.

“On April 29, 2026, TELA Bio, Inc. (the " Company ") issued a press release announcing its preliminary unaudited revenue for the quarter ended March 31, 2026 of approximately $19.0 million.”

Paul Thomas was appointed as Director at TELA Bio, Inc..

“On April 29, 2026, in connection with the Resigning Directors’ resignations, the Board appointed Guido Neels as a Class II director, with a term expiring at the 2027 Annual Meeting of the Company, and Guy Nohra and Paul Thomas as Class III directors...”

Guy Nohra was appointed as Director at TELA Bio, Inc..

“On April 29, 2026, in connection with the Resigning Directors’ resignations, the Board appointed Guido Neels as a Class II director, with a term expiring at the 2027 Annual Meeting of the Company, and Guy Nohra and Paul Thomas as Class III directors...”

Guido Neels was appointed as Director at TELA Bio, Inc..

“On April 29, 2026, in connection with the Resigning Directors’ resignations, the Board appointed Guido Neels as a Class II director...”

Federica O'Brien resigned as Director at TELA Bio, Inc..

“In addition, on April 29, 2026, Kurt Azarbarzin, Vince Burgess and Federica O’Brien (the “ Resigning Directors ”) each tendered his or her resignation from the Board...”

Vince Burgess resigned as Director at TELA Bio, Inc..

“In addition, on April 29, 2026, Kurt Azarbarzin, Vince Burgess and Federica O’Brien (the “ Resigning Directors ”) each tendered his or her resignation from the Board...”

Kurt Azarbarzin resigned as Director at TELA Bio, Inc..

“In addition, on April 29, 2026, Kurt Azarbarzin, Vince Burgess and Federica O’Brien (the “ Resigning Directors ”) each tendered his or her resignation from the Board...”

Doug Evans resigned as Chairman of the Board at TELA Bio, Inc..

“On April 29, 2026, Doug Evans, Chairman of the Board of Directors (the “ Board ”) of the Company, notified the Company and the Board that he will not stand for re-election at the Company’s 2026 Annual Meeting of Stockholders (the “ 2026 Annual Meeting ”) and will retire from the Board...”

TELA Bio, Inc. reported financial results for the fourth quarter of 2025 and the fiscal year ended December 31, 2025.

“On March 24, 2026, TELA Bio, Inc. (the " Company ") issued a press release announcing its financial results for the fourth quarter of 2025 and the fiscal year ended December 31, 2025.”

TELA Bio, Inc. received a nasdaq deficiency notice notice regarding minimum bid price (rules 5450(a)(1)).

“March 17, 2026, TELA Bio, Inc. (the “ Company ”) received a deficiency letter from the Nasdaq Listing Qualifications Department (the “ Staff ”) of the Nasdaq Stock Market LLC (“ Nasdaq ”) notifying the Company that, for the last 30 consecutive business days, the closing bid price for the Company’s common stock has been below the minimum $1.00 per share required for continued listing on The Nasdaq Global Market pursuant to Nasdaq Listing Rule 5450(a)(1) (“ Rule 5450(a)(1) ”). The Nasdaq deficiency letter has no immediate effect on the listing of the Company’s common stock, and its common stock”

TELA Bio, Inc. issued up to 333,333 shares of warrant to Perceptive Credit Holdings V, LP for in connection with the Delayed Draw Loan.

“the Company will issue to Perceptive warrants to purchase up to 333,333 shares of its Common Stock, with an exercise price of $1.11”

Antony Koblish changed role as President at TELA Bio, Inc..

“Antony Koblish, the Company’s current President and Chief Executive Officer, will continue in his role as Chief Executive Officer, but as of the Effective Date will no longer hold the title of President.”

Jeffrey Blizard was appointed as President at TELA Bio, Inc..

“the Board appointed Jeffrey Blizard as the new President of the Company, effective as of June 2, 2025”

Jeffrey Blizard resigned as Director at TELA Bio, Inc..

“Jeffrey Blizard, a member of the Board of Directors (the “ Board ”) of TELA Bio, Inc. (the “ Company ”), tendered his resignation from the Board, effective as of June 2, 2025.”

Jeffrey Blizard was appointed as member of the Board of Directors at TELA Bio, Inc..

“On June 4, 2024, TELA Bio, Inc. (the “ Company ”) appointed Jeffrey Blizard as a member of the Company’s Board of Directors (the “ Board ”).”

TELA Bio, Inc. reported first quarter ended March 31, 2024 results: revenue $16.6 million, net income $5.7 million. Guidance raised.

“Revenue was $16.6 million in the first quarter of 2024, an increase of 39% compared to the same period in 2023. The increase was due to an increase in unit sales of our products and the continued expansion of the commercial organization, which resulted in increased penetration of existing customer accounts, the addition of new customers, and growing international sales. Gross profit was $11.3 million in the first quarter of 2024, or 68% of revenue, compared to $7.9 million, or 66% of revenue, in the same period in 2023. The increase in gross margin was primarily due to a lower charge for excess and obsolete inventory as a percentage of revenue due to improvements in inventory management. Operating expenses were $23.7 million in the first quarter of 2024, compared to $19.2 million in the same period in 2023. The increase was due to higher compensation costs and employee-related expenses from additional headcount as we continue to expand our organization, as well as increased travel, con”

TELA Bio, Inc. reported the fiscal year ended December 31, 2023 results: revenue $58.5 million, net income $46.7 million. Guidance initiated.

“Revenue was $58.5 million for the full year 2023, an increase of 41% compared to the same period in 2022. The increase was primarily due to an increase in unit sales of our products and the continued expansion of the commercial organization, which resulted in increased penetration of existing customer accounts, the addition of new customers, and growing international sales. Gross profit was $40.1 million in the full year 2023, or 69% of revenue, compared to $27.0 million, or 65% of revenue, in 2022. The increase in gross margin was primarily due to improved inventory management processes and lower amortization of intangible assets. Operating expenses were $84.2 million in the full year of 2023, compared to $66.1 million in 2022. The increase was due to higher compensation costs and employee-related expenses from additional headcount as we continue to expand our organization, as well as increased travel, consulting and professional fees. Loss from operations was $44.1 million in the ful”

TELA Bio, Inc. reported the fourth quarter of 2023 results: revenue $17.0 million, net income $12.9 million. Guidance initiated.

“Revenue was $17.0 million in the fourth quarter of 2023, an increase of 46% compared to the same period in 2022. The increase was due to an increase in unit sales of our products and the continued expansion of the commercial organization, which resulted in increased penetration of existing customer accounts, the addition of new customers, and growing international sales. Gross profit was $11.6 million in the fourth quarter of 2023, or 68% of revenue, compared to $8.2 million, or 70% of revenue, in the same period in 2022. The slight decrease in gross margin was primarily due to an increase in our excess and obsolete inventory adjustments. Operating expenses were $23.9 million in the fourth quarter of 2023, compared to $17.6 million in the same period in 2022. The increase was due to higher compensation costs and employee-related expenses from additional headcount as we continue to expand our organization, as well as increased travel, consulting and professional fees. Loss from operatio”

TELA Bio, Inc. reported third quarter ended September 30, 2023 results: revenue $15.1 million, net income $11.0 million. Guidance reaffirmed.

“the preservation and restoration of the patient's own anatomy, today reported financial results for the third quarter ended September 30, 2023. Recent Highlights · Revenue of $15.1 million in the third quarter, representing growth of 35% over the third quarter of 2022 – the 11th consecutive quarter of 35% or greater year-over-year growth; · Demand for OviTex® and”

TELA Bio, Inc. amended Fourth Amendment to Lease Agreement with WPT Land 2 LP (effective 2023-10-18).

“On October 18, 2023, TELA Bio, Inc. (the “ Company ”) and WPT Land 2 LP (the “ Landlord ”) entered into a Fourth Amendment to Lease Agreement (the “ Fourth Amendment ”), amending that certain Lease Agreement, dated January 31, 2013 (as subsequently amended, the “ Lease Agreement ”) relating to the Company’s corporate headquarters located at 1 Great Valley Parkway, Malvern, Pennsylvania 19355.”

John Nosenzo resigned as Director at TELA Bio, Inc..

“On September 22, 2023, John Nosenzo, a member of the Board of Directors (the “Board”) of TELA Bio, Inc. (the “Company”), tendered his resignation from the Board, effective immediately.”

TELA Bio, Inc. shareholders approved Ratification of Independent Registered Public Accountants at the 2023-06-01 meeting.

“The appointment of KPMG LLP as the Company’s independent registered public accounting firm for the 2023 fiscal year was ratified, as follows: Votes For Votes Against Abstentions Broker Non-Votes 17,188,505 3,312 1,957 –”

TELA Bio, Inc. shareholders approved Election of Class I Directors at the 2023-06-01 meeting.

“Each of Lisa Colleran and Doug Evans were elected to the Board to serve as Class I directors until the 2026 Annual Meeting of Stockholders and until their successors, if any, are elected or appointed, or their earlier death, resignation, retirement, disqualification or removal, as follows: Name For Withheld Broker Non-Votes Lisa Colleran 14,316,642 1,055,675 1,821,457 Doug Evans 13,535,182 1,837,135 1,821,457”

TELA Bio, Inc. reported the first quarter ended March 31, 2023 results: revenue $11.9 million, net income $12.0 million. Guidance reaffirmed.

“First Quarter 2023 Financial Results Revenue was $11.9 million in the first quarter of 2023, an increase of 45% compared to the same period in 2022. The increase was due to the expansion of our commercial organization, the addition of new customers, increased penetration within existing customer accounts, and stronger international sales. Gross profit was $7.9 million in the first quarter of 2023, or 66% of revenue, compared to $5.0 million, or 61% of revenue, in the same period in 2022. The increase in gross margin was primarily due to better inventory management practices resulting in a decrease in the reserve for excess and obsolete inventory as a percentage of revenue as compared to the prior year period. Operating expenses were $19.2 million in the first quarter of 2023, compared to $14.8 million in the same period in 2022. The increase was due to higher compensation and employee-related expenses from additional headcount as we continue to expand our organization, along with incre”

TELA Bio, Inc. entered into Underwriting Agreement with Jefferies LLC, Piper Sandler & Co. and Lake Street Capital Markets, LLC, as representatives of the several underwriters valued at approximately $42.1 million (effective 2023-04-18).

“On April 18, 2023, TELA Bio, Inc. (the “ Company ”) entered into an underwriting agreement (the “ Underwriting Agreement ”) with Jefferies LLC, Piper Sandler & Co. and Lake Street Capital Markets, LLC, as representatives of the several underwriters listed in Schedule A thereto (the “ Underwriters ”) pursuant to which the Company agreed to issue and sell 4,750,000 shares of the Company’s common stock, par value $0.001 per share (the “ Common Stock ”), to the Underwriters (the “ Offering ”).”

TELA Bio, Inc. reported the first quarter ended March 31, 2023 results: revenue $11.9 million.

“Revenue for the three months ended March 31, 2023 is estimated to be $11.9 million, compared to $8.2 million over the corresponding period of 2022.”

TELA Bio, Inc. reported Full year 2023 results: revenue $60 million to $65 million. Guidance initiated.

“Full year 2023 revenue is projected to range from $60 million to $65 million, reflecting growth of 45% to 57% over full year 2022.”

TELA Bio, Inc. reported the full year ended December 31, 2022 results: revenue $41.4 million, net income $44.3 million.

“Revenue was $41.4 million for the full year 2022, an increase of 41% compared to the full year 2021.”

TELA Bio, Inc. reported the fourth quarter of 2022 results: revenue $11.6 million, net income $10.0 million.

“Revenue was $11.6 million in the fourth quarter of 2022, an increase of 39% compared to the same period in 2021.”

TELA Bio, Inc. reported the third quarter ended September 30, 2022 results: revenue $11.2 million, net income $10.7 million. Guidance reaffirmed.

“and restoration of the patient's own anatomy, today reported financial results for the third quarter ended September 30, 2022. Recent Highlights · Reported revenue of $11.2 million for the third quarter, representing growth of 46% over the same quarter of 2021; · Increased demand for OviTex ® and OviTex PRS Reinforced Tissue Matrix products in the third”

Megan Smeykal was appointed as Chief Accounting Officer at TELA Bio, Inc..

“Effective January 1, 2022, the Board of Directors of TELA Bio, Inc. (the “Company”) appointed Megan Smeykal as the Company’s Chief Accounting Officer and principal accounting officer.”

Megan Smeykal changed role as Vice President – Corporate Controller at TELA Bio, Inc..

“Effective upon Mr. Cuca’s employment, Megan Smeykal, the Company’s Vice President – Corporate Controller, will cease performing the duties of the principal financial officer of the Company.”

Roberto Cuca was appointed as Chief Financial Officer and Chief Operating Officer at TELA Bio, Inc..

“announced the appointment of Roberto Cuca as Chief Financial Officer and Chief Operating Officer of the Company, effective September 27, 2021.”